I agree with that too Dunoverwe are in multiple trials across...

I agree with that too Dunover

we are in multiple trials across various conditions DiPG is just one - but also the focus due to no advancement in the treatments for some 20 years... it’s a door opener. and once we are used in one treatment the application of this medicine will be used in other other conditions and probably various off label uses... its safety profile proven.

as any one here well knows I’m excited by the excitement of the various collaboration research teams focused to Paxalisib as a potential treatment... particularly since they do not ‘own’ the drug and therefore one assumes would drop it like a hot potato if it didn’t offer value to their research... they care little for SP or previous company releases or investments.

the market will catch up eventually